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Abstract
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized
countries. The ‘‘wet’’ AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and
severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF-A) in CNV development has been
established and VEGF-A neutralization has become the standard care for wet AMD. Recently, CCR3 was reported to play an
important role in CNV development and that CCR3 targeting was reported to be superior to VEGF-A targeting in CNV
suppression. We investigated the role of CCR3 in CNV development using the Matrigel induced CNV and found that in both
rats and mice, CNV was well-developed in the control eyes as well as in eyes treated with CCR3 antagonist SB328437 or
CCR3 neutralizing antibodies. No statistically significant difference in CNV areas was found between the control and
SB328437 or CCR3-ab treated eyes. Immunostaining showed no specific expression of CCR3 in or near CNV. In contrast, both
VEGF-A neutralizing antibodies and rapamycin significantly suppressed CNV. These results indicate that CCR3 plays no
significant role in CNV development and question the therapeutic approach of CCR3 targeting to suppress CNV. On the
other hand, our data support the therapeutic strategies of VEGF-A and mTOR (mammalian target of rapamycin) targeting
for CNV.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of
blindness in the elderly in the developed world [1]. AMD presents
in two distinct forms: the geographic atrophy and the exudative
AMD. The geographic atrophy, also known as the ‘‘dry’’ form of
AMD, is characterized by atrophy of the central retina. The
exudative or ‘‘wet’’ AMD, a major cause of severe vision loss, is
identified by the presence of choroidal neovascularization (CNV),
new blood vessels originated from the choroid that invade the
macula area. Development of CNV leads to retinal edema and
may eventually destroy the structure of the retina, resulting in
irreversible loss of central vision due to hemorrhage, retinal
detachment and disciform scar formation.
Compiling evidence indicates clearly that VEGF-A, the major
regulator of vasculogenesis and angiogenesis [2], plays a critical
role in CNV development [3,4,5]. In animal CNV models,
blocking VEGF-A by pharmacological agents not only effectively
inhibits CNV [6,7], but also induces regression of the newly
developed CNV [8]. Clinically, neutralization of VEGF-A has
become the standard care for wet AMD [9,10,11,12,13,14].
CCR3 is a G protein coupled receptor that expressed mainly in
eosinophils, basophils, a subset of Th2 lymphocyts, and mast cells,
with the highest levels in eosinophils [15,16,17]. It binds to
several CC ligands and is believed to function in recruiting
leukocytes, mainly the Th2 cells and eosinophils, to inflammatory
sites, and in allergic asthma, atopic dermatitis, and allergic
rhinitis [15,17,18]. It is also found in vascular endothelial cells,
including human microvascular endothelial cells, and has been
shown to be involved in angiogenesis [19]. Recently, Takeda and
colleagues reported that CCR3 played a critical role in CNV
development [20]. They showed that CCR3 was specifically
expressed in choroidal neovascular endothelial cells in tissues
from human AMD patients. They also demonstrated that
blocking CCR3 suppressed new vessel formation both in cultured
human choroidal endothelial cells and in laser-induced CNV in
mouse. In addition, their data indicated that CCR3 targeting was
superior to VEGF-A neutralization in CNV suppression [20].
These investigators thus believe that CCR3 is a target for AMD
therapy [20].
We studied the role of CCR3 in CNV development in Matrigel
CNV model in both rat and mouse. In the model, CNV is induced
by subretinal injection of Matrigel, as described in detail recently
[8]. Here we report that blocking CCR3 with either a small
molecular antagonist SB328437 or CCR3 neutralizing antibodies
(CCR3-ab) failed to inhibit CNV in both rat and mouse. On the
other hand, VEGF-A neutralizing antibodies (VEGF-ab) effica-
ciously inhibited CNV development in the Matrigel model.
Rapamycin, a known CNV inhibitor [21], was also very effective
in suppressing CNV development. Our results therefore argue
against the role of CCR3 in CNV development and question
whether CCR3 targeting is a viable therapeutic approach for
CNV.
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Development of CNV in the Matrigel model
In the Matrigel model, CNV was induced by injection of
Matrigel into the subretinal space [8,22] (Fig. 1, see Materials and
Methods for details). Angiogenic sprouts are detected 4 days after
injection. The CNV network is well developed 10 days after
injection and increases progressive in size [8]. Figure 2 shows a
typical CNV network in the Matrigel injected area. A DIC
(differential interference contrast) image of this 100 mm-thick
section displays the location of injected Matrigel related to the
choroid and the retina (Fig. 2A). A fluorescent confocal image
(Fig. 2B) shows the induced CNV along with the choroidal and
retinal vasculature. The site indicated by a white arrow in Fig. 2B
clearly shows that the neovasculature originated from choriocap-
illaris. The CNV network is better appreciated in Fig. 2C in which
the two images in Fig. 2A and 2B were merged, and in Fig. 2D in
which a 3-D image of the blood vessels in the entire thickness of
the section was reconstructed.
Hyperpermeability of newly developed CNV
Newly formed blood vessels are highly permeable because of the
influence of VEGF-A (also known as vascular permeability factor
or VPF) [23,24]. The permeability of the subretinal Matrigel-
induced CNV was examined with Evans Blue [25], a dye that
tightly binds to albumin. A representative image of a choroid-
retina preparation is shown in Fig. 3. Evans Blue signal is
concentrated in Matrigel injected area, demonstrating the
hyperpermeability of Matrigel-induced CNV.
CCR3 targeting and CNV development in rat
To investigate whether CCR3 targeting blocks CNV develop-
ment, we used a small molecule CCR3 antagonist SB328437 and
specific CCR3-ab at the doses reported to inhibit CNV
development by Takeda and colleagues that [20]. Surprisingly,
no inhibition of CNV was seen in eyes treated with either
SB328437 or CCR3-ab (Fig. 4A, 4B and 4C). In contrast, minimal
CNV was seen in VEGF-ab treated eyes (Fig. 4D), and in eyes
treated with rapamycin (Fig. 4E). In fact, CNV was completely
absent in 10 out of 14 eyes treated with VEGF-A antibodies, and
in 13 out of 16 eyes treated with rapamycin.
Quantitatively, the CNV area is 3.6361.64 (610
5 mm
2, n=13)
in the control eyes. In the eyes treated with SB328437 or CCR3-
Figure 1. Schematic illustration of subretinal injection of
Matrigel. The tip of a blunt needle (A, arrow) is introduced to the
subretinal space (Sp) at a shallow angle toward the posterior pole.
Injected Matrigel pushes its way to form a bleb in the subretinal space
(M, dark shaded area). A sharp needle (B, arrow) is used to break the
Bruch’s membrane (A and B, arrowhead) in the center of the Matrigel
bleb after Matrigel injection (B). S: sclera; Ch: choroid; R: retina, M:
Matrigel.
doi:10.1371/journal.pone.0017106.g001
Figure 2. CNV induced by subretinal Matrigel. Eyes were collected 10 days after subretinal injection of Matrigel in Sprague-Dawley rats. A DIC
image (A) shows injected Matrigel (M) and the layers of the eye, including the sclera (S), choroid (Ch), and the retina (R). CNV is clearly shown by DiI
staining, along with choroidal and retina vasculature (B) The site where the CNV entered the Matrigel area is indicated by an arrowhead (B). A merged
image of A and B is presented in C to show the structure of the eye related to the CNV. A 3D image of the vasculature in the entire thickness of the
section was reconstructed in panel D. Scale bar: 100 mm.
doi:10.1371/journal.pone.0017106.g002
CCR3 and CNV
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respectively (Fig. 5). In comparison, the CNV areas are 0.1960.32
(n=14) in the eyes treated with VEGF-ab, and 0.0560.12 (n=16)
in rapamycin-treated eyes (Fig. 5). No statistically significant
difference in CNV area was found between the control group and
the group treated with SB328437 or CCR3-ab (Fig. 5). On the
other hand, both VEGF-ab and rapamycin treatment significantly
suppressed CNV development, as compared to the untreated
group as well as the groups treated with SB 328437 or CCR3
antibodies (Fig. 5).
Dose range studies of the CCR3 inhibitors SB328437 and
CCR3-ab showed no statistically significant difference between
control eyes and treated eyes in either the SB328437 or the
CCR3-ab group (Fig. 6). The CNV area is 2.9061.24 (610
5 mm
2,
n=5) in eyes injected with DMSO control (2.5% final concen-
tration, equal to the amount of DMSO in Matrigel containing
10 mg/ml SB328437). In eyes treated with 0.1, 1, or 10 mg/ml
SB328437, the CNV areas are 3.8561.78 (n=5), 3.5661.61
(n=6), and 3.3961.45 (n=7), respectively (Fig. 6A). The CNV
area is 4.2461.80 (n=6) in the eyes injected with isotype IgG
control (1 mg/ml). In eyes treated with 0.1 or 1 mg/ml CCR3-ab,
the CNV areas are 3.7961.75 (n=6) and 4.2361.41 (n=5),
respectively (Fig. 6B).
The expression of CCR3 in choroidal neovascular endothelial
cells was examined by CCR3 immunostaining. No specific
immunoreactivity of CCR3 was found in and around the CNV
blood vessels (Fig. 7A, 7B and 7C) whereas CCR3 immnor-
Figure 3. Hyperpermeability of CNV. Rats were injected with
Matrigel to the subretinal space. Ten days later, Evans Blue (60 mg/kg,
i.v.) was give for 30 min before eyes were harvested. Evans Blue
fluorescence in the choroid-retina preparation is concentrated in the
Matrigel injected area, indicating hyperpermeability of CNV. The needle
site is indicated (arrowhead). Scale bar: 500 mm.
doi:10.1371/journal.pone.0017106.g003
Figure 4. Effects of CCR3, VEGF-A, or mTOR inhibition on CNV in rats. Eyes were injected with Matrigel alone or mixed with SB328437, CCR3-
ab, VEGF-ab, or rapamycin, and collected 12 days later. Extensive CNV was seen in the control eyes (A) as well as the eyes treated with SB328437 (B),
CCR3-ab (C). In contrast, minimal CNV was found in eyes treated with VEGF-ab (D) or rapamycin (E). The width of CNV is indicated by a horizontal bar
in each section. The layers of the eye, including the choroids (Ch), the Matrigel layer (M), and the retina (R), are indicated by vertical white bars in
panel A. Scale bar: 200 mm.
doi:10.1371/journal.pone.0017106.g004
CCR3 and CNV
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not specifically expressed in the CNV endothelial cells.
CCR3 targeting and CNV development in mouse
The failure of CCR3 targeting to inhibit CNV in rat prompted
us to investigate whether CCR3 targeting could suppress CNV in
mouse. Like in rat, subretinal injection of Matrigel induced
extensive CNV in mouse (Fig. 8A). Again, no inhibition of CNV
was seen in the eyes treated with either SB328437 or CCR3-ab
(Fig. 8A and 8B). In contrast, significant CNV suppression was
seen in rapamycin treated eyes. Among the 10 eyes treated with
rapamycin, CNV is absent in 9 and only minimal CNV was found
in one eye (Fig. 8D). Quantitatively, the CNV area is 1.2960.92
(610
5 mm
2, n=14) in the control eyes, 2.0362.1 (n=15) in
SB328437-treated eyes, and 2.261.89 (n=22) in eyes treated with
CCR3-ab (Fig. 9). In rapamycin-treated eyes, the CNV area is
0.00860.024 (n=10) (Fig. 9). No statistically significant difference
is found in CNV areas between control eyes and eyes treated with
either SB328437 or CCR3-ab (Fig. 9). In contrast, rapamycin
treatment significantly suppressed CNV development, as com-
pared to the control eyes and eyes treated with SB328437 or
CCR3 antibodies (Fig. 9). These results are consistent with the
data from rats and demonstrate that CCR3 is not critically
involved in CNV development.
Discussion
We have demonstrated that CCR3 targeting with either CCR3
neutralizing antibodies or high affinity CCR3 specific antagonist
SB328437 has no inhibitory effect on CNV development in the
subretinal Matrigel induced CNV in both rat and mouse. In
addition, CCR3 expression was not detected in the CNV
endothelial cells in our experiments. These results strongly argue
against a critical role of CCR3 in CNV development and raise a
question as to whether CCR3 is a valid therapeutic target for
CNV. On the other hand, we have confirmed the role of VEGF-A
in CNV development and that VEGF-A targeting is an effective
approach to suppress CNV. Rapamycin, an mTOR inhibitor, is
also efficacious in CNV inhibition.
CNV induction by subretinal Matrigel was first reported by
Wen and colleagues in rat (Wen et al. IOVS 2002; 43:ARVO E-
abstract 1297). In rabbits, subretinal Matrigel induces highly
permeable neovescularization, as assessed by fluorescein leakage
that lasted for weeks in some animals [26], consistent with the
hyperpermeability of CNV found in the present work (Fig. 3).
Subretinal Matrigel also induces RPE migration which eventually
form a new RPE monolayer between photoreceptors and Matrigel
and effectively turns the Matrigel location from subretinal to sub-
RPE [22]. The Matrigel CNV model in rat has been characterized
in detail in a recent report, showing that CNV in subretinal
Matrigel progressively increases in size, accompanied by an
increase in lesion size, a progressive infiltration of leukocytes and
Figure 5. Quantification of CNV area in rats. The CNV areas were
measured and calculated. No statistically significant difference was
found between the control and either the SB328437 or the CCR3-ab
group. On the other hand, the CNV areas of the VEGF-ab and the
rapamycin group are significantly smaller than that of the control eyes
(double asterisks, P,0.01) or eyes treated with SB328437 or CCR3-ab
(triple asterisks, P,0.001).
doi:10.1371/journal.pone.0017106.g005
Figure 6. Dose range studies. Rat eyes were collected 12 days after
injection of Matrigel with different doses of SB328437 or CCR3-ab. CNV
was well developed in eyes injected with DMSO control (DMSO) and
eyes treated with 0.1, 1, or 10 mg/ml SB328437 (A), as well as in eyes
treated with isotype IgG control (IgG) and 0.1 and 1 mg/ml CCR3-ab (B).
No statistically significant difference was found between the control
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resemble the inflammatory reaction and fibrosis in wet AMD in
patients. Thus, the Matrigel model closely mimics the CNV in wet
AMD. VEGF-A neutralization and rapamycin treatment effec-
tively suppressed CNV in the Matrigel model (reference [8] and
present work), consistent with data from the laser-induced CNV
Figure 7. Expression of CCR3. Rat eyes were collected 12 days after injection of Matrigel. Cryosections were stained for CCR3 immunoreactivity. A
well-developed new blood vessel is clearly present in the Matrigel injected area as revealed by DiI staining (A, arrowhead). No specific CCR3
immunoreactivity was detected in or around the blood vessel (B). A merged image of A, B, with a DIC image was presented in C (arrowhead indicates
CNV). CCR3 positive staining is evident in a section of the spleen (D), which serves as a positive control. M, Matrigel area; Ch, choroid; S, sclera. Scale
bar: 50 mm.
doi:10.1371/journal.pone.0017106.g007
Figure 8. Effects of CCR3 or mTOR inhibition on CNV in mice. Eyes were injected with Matrigel alone or mixed with SB328437, CCR3-ab, or
rapamycin, and collected 12 days later. Extensive CNV was seen in the control eyes (A) as well as the eyes treated with SB328437 (B), or CCR3-ab (C). In
contrast, minimal CNV was found in eyes treated with rapamycin (D). The width of CNV is indicated by a horizontal bar in each section. The layers of
the eye, including the choroids (Ch), the Matrigel area (M), and the retina (R), are indicated by vertical white bars in panel A. Scale bar: 200 mm.
doi:10.1371/journal.pone.0017106.g008
CCR3 and CNV
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CNV models. Therefore, the discrepancy between our findings in
the Matrigel CNV model and data reported by Takeda and
colleagues in the laser-induced CNV model is unlikely due to the
difference between the two CNV models. Our results that CCR3
targeting is ineffective in CNV inhibition in two species indicate
that CCR3 is not critically involved in CNV development in
general.
The results that VEGF-A neutralization effectively inhibited
CNV development in both rat and mouse are consistent with
many previous studies and confirm the critical role of VEGF-A in
CNV development and maintenance. Thus, our present work
provides additional support for VEGF-A targeting as a therapeutic
strategy for wet AMD.
Rapamycin, originally identified as an antifungal agent [27], is a
potent immunosuppressant [28,29]. It forms a complex with the
FK506 binding protein (FKBP-12) and then binds to mTOR
(mammalian target of rapamycin) and interferes with its signaling
[30]. As the central part of a complex intracellular pathway,
mTOR is involved in the regulation of cell growth, metabolism,
autophagy, and angiogenesis [31]. Studies have shown that
rapamycin inhibits VEGF-A expression, VEGF receptor activa-
tion, and vascular endothelial cell proliferation [32,33,34,35]. In
addition, rapamycin inhibits HIF-1 expression, leading to
inhibition of VEGF-A synthesis [35,36]. Our results that
rapamycin almost completely inhibited CNV development are
consistent with a previous report that systemically administered
rapamycin significantly suppressed laser-induced model of CNV in
mouse [21], indicating that mTOR targeting is a potential
treatment for CNV.
The report by Takeda and colleagues [20] was received with
caution [37]. Our attempts to verify the role of CCR3 in CNV in
the Matrigel model yield consistent negative results in two species,
leading us to conclude that CCR3 is not critically involved in
CNV development and maintenance and therefore CCR3
targeting is not a viable therapeutic approach for CNV. Our
results, however, support the therapeutic strategies for CNV by
VEGF-A and mTOR targeting.
Materials and Methods
Ethics Statement
All procedures involving animals adhered to Association for
Research in Vision and Ophthalmology Statement for the Use of
Animals in Ophthalmic and Vision Research and were approved
by the Institutional Animal Care and Use Committee of University
of Miami, Miller School of Medicine (07-232).
Animals and subretinal injection of Matrigel
Adult Sprague Dawley rats and BALB/c mice (Charles River
Laboratories, Wilmington, MA) were used in all experiments.
CNV was induced by subretinal injection of Matrigel, as
previously described [8,22]. Briefly, animals were anesthetized
with ketamine (40 mg/kg, i.p) and xylazine (6 mg/kg, i.p.). A
33G needle was used to make an insertion at the equator on the
temporal side of an eye to reach the subretinal space. A blunt
33G needle attached to a 10-ml Hamilton micro-syringe was then
introduced through the insertion to the subretinal space. Matrigel
(growth factor reduced, BD Biosciences, Bedford, MA), diluted
with phosphate buffered saline (PBS) or PBS containing CCR3,
VEGF-A inhibitors, or rapamycin, at 3:1 (75% gel), was slowly
injected to form a bleb (volume of injection: 1.2 ml for rats, 0.8 ml
for mice) (Fig. 1). The injecting needle was kept in place for 1–
2 min for the gel to solidify before withdrawn. To synchronize
the CNV development, an additional insertion at the center of
the Matrigel injected area was made with a sharp 33G needle
(Fig. 1).
CCR3 and VEGF-A inhibition
CCR3 specific antagonist (S)-methyl-2-naphthoylamino-3-(4-
nitrophenyl) propionate (SB328437, Calbiochem, San Diego, CA)
or CCR3 neurtralizing antibodies (clone 83103, R & D Systems,
Minneapolis, MN) was used for CCR3 inhibition. VEGF-A was
blocked by VEGF-A neutralizing antibodies (R & D Systems).
CCR3-ab or VEGF-ab was dissolved in PBS and then mixed with
Matrigel before injection (1 mg/ml final concentration). SB 328437
or rapamycine (LC Laboratories, Woburn, MA) was dissolved in
dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO),
diluted in PBS, and then mixed with Matrigel before injection.
Visualization of blood vessels
Blood vessels were labeled with a DiI solution (1, 19-
Dioctadecyi-3, 3, 39,3 9-tetramethylindocarbocyanine perchlorate,
Sigma-Aldrich), as described [38]. Briefly, animals were killed by
CO2 overdose and perfused with PBS, followed by the DiI
solution. Tissues were fixed by subsequent perfusion with 4%
paraformaldehyde (in 0.1 M phosphate buffer, pH 7.4). Eyecups
were obtained by removing the anterior segment of the eye and
post-fixed in the same fixative overnight, rinsed with PBS, and
embedded in 5% agarose. Serial sections (100 mm) covering the
entire Matrigel area were cut on a vibratome (VT1000S, Leica
Microsystems, Bannockburn, IL), mounted on glass slides with
80% glycerol, and examined by confocal microscopy.
Figure 9. Quantification of CNV area in mice. The CNV areas were
measured and calculated. No statistically significant difference was
found between the control and the SB328437 or the CCR3-ab group. On
the other hand, the CNV area in the rapamycin group is significantly
smaller than that in the control eyes (double asterisks, P,0.01) or eyes
treated with SB328437 or CCR3-ab (triple asterisks, P,0.001).
doi:10.1371/journal.pone.0017106.g009
CCR3 and CNV
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CNV area was calculated through the entire Matrigel area, as
described [8]. The CNV area of a section (Ci) was estimated by
multiplying the ‘‘width’’ (Wi), the maximal measurement of CNV
along the sclera, by the ‘‘thickness’’ of the section Ti (Ci=T i Wi).
The height of CNV, the maximal distance between Bruch’s
membrane and the front edge of CNV, was not included since its
variation was negligible. The thickness of each section (100 mm),
Ti, was the same for all sections as T. The entire CNV area of each






The permeability of CNV was examined with Evans Blue. Eyes
of Sprague-Dawley rats were injected with Matrigel and 10 days
later, Evans Blue (60 mg/kg in PBS) was given intravenously.
Animals were killed 30 min after Evans Blue injection and
perfused with PBS to clear the Evans Blue in the circulation
system, followed by 4% paraformaldehyde (in 0.1 M phosphate
buffer, pH 7.4) perfusion. Eyes were harvested and the anterior
segments removed. Choroid-retina preparations were dissected,
flat-mounted and examined by fluorescence microscopy.
Immunostaining
Expression of CCR3 in the CNV endothelial cells was
examined by immunostaining using antibodies against CCR3
(Santa Cruz Biotechnologies, Santa Cruz, CA) and visualized with
Alexa fluor 647 conjugated secondary antibodies (Invitrogen,
Carlsbad, CA). Eyecups were prepared as described above.
Cryosections of 30 mm were cut and mounted on glass slides.
Sections were rinsed in PBS and incubated in the primary anti-
CCR3 antibodies (1:50 dilution) at 4uC overnight, then in
secondary antibodies (1:250 dilution) at 4uC overnight. Sections
were examined by confocal microscopy.
Statistical Analysis
Results were analyzed by Kruskal-Wallis test followed by
Dunn’s test post hoc multiple analyses for comparisons between
different groups, using InStat3 (GraphPad Software Inc., San
Diego, CA). Data are expressed as mean6SD.
Author Contributions
Conceived and designed the experiments: YL RW. Performed the
experiments: YL DH XX ZW LL RW. Analyzed the data: YL DH RW.
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